Celgene Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8,852

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $80.3B

Celgene General Information

Description

Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets drugs to treat multiple myeloma and a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma.

Contact Information

Website
www.celgene.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 86 Morris Avenue
  • Summit, NJ 07901
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celgene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 20-Nov-2019 $80.3B 00.000 000.00 Completed Profitable
10. Debt - Acquisition 08-Feb-2018 00.00 00.000 Completed Profitable
9. Debt Refinancing 31-Oct-2017 000 00.000 Completed Profitable
8. Debt Refinancing 01-Aug-2017 00000 00.000 Completed Profitable
7. Debt - Acquisition 03-Aug-2015 000 00.000 Completed Profitable
6. General Corporate Purpose 06-May-2014 00.00 00.000 Completed Generating Revenue
5. General Corporate Purpose 01-Aug-2013 00.00 00.000 Completed Generating Revenue
4. Debt Refinancing 07-Aug-2012 00.00 00.000 Completed Generating Revenue
3. PIPE $12.7M Completed Profitable
2. IPO 28-Jul-1987 $12.7M $12.7M Completed Generating Revenue
To view Celgene’s complete valuation and funding history, request access »

Celgene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets d
Drug Discovery
Summit, NJ
8,852 As of 2018
00.000
000.00 0000-00-00
000000&0 00.000

000000

uis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu f
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000.00 0000-00-00
000000&0 00.000

000000

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
000000000000000
Wilmington, DE
0000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celgene Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seagen Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
Incyte Formerly VC-backed Wilmington, DE 0000 00000 00000000000 00000
Gilead Sciences Formerly VC-backed Foster City, CA 00000 000.00 0000
Merck & Co. Corporation Rahway, NJ 00000 0000 000000000 - 0000
Emmaus Life Sciences Formerly VC-backed Torrance, CA 00 000.00 000000000 - 000.00
You’re viewing 5 of 27 competitors. Get the full list »

Celgene Patents

Celgene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240208937-A1 Compounds and their use for treatment of hemoglobinopathies Pending 04-Nov-2022 0000000000
US-20240190890-A1 Mk2 inhibitors and uses thereof Pending 27-Oct-2022 0000000000
US-20240109881-A1 Heteroaryl compounds as ligand directed degraders of irak4 Pending 20-Jul-2022 0000000000
US-20240025851-A1 Modulators of bcl6 as ligand directed degraders Pending 28-Apr-2022 0000000000
CA-3227684-A1 Process for preparing histone demethylase inhibitors Pending 18-Aug-2021 C07D405/12
To view Celgene’s complete patent history, request access »

Celgene Board Members (18)

Name Representing Role Since
Carrie Cox Self Board Member 000 0000
Rodman Drake Celgene Board Member 000 0000
You’re viewing 2 of 18 board members. Get the full list »

Celgene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celgene Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Asseily Ventures Venture Capital Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
Edelson Technology Partners Venture Capital Minority 000 0000 000000 0
Ridgeback Capital Venture Capital Minority 000 0000 000000 0
To view Celgene’s complete investors history, request access »

Celgene Investments & Acquisitions (127)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aitia 07-Jan-2020 00000 0000 0000 Drug Discovery
Oncorus 20-Dec-2019 00000 0000 000.00 Biotechnology
Cyteir Therapeutics 15-Oct-2019 00000 0000 000.00 Drug Discovery 00000 000
Anokion 11-Sep-2019 00000 0000 000.00 Drug Discovery
RAPT Therapeutics 18-Jun-2019 Later Stage VC 0000 Drug Discovery
You’re viewing 5 of 127 investments and acquisitions. Get the full list »

Celgene Subsidiaries (2)

Company Name Industry Location Founded
Acetylon Pharmaceuticals Drug Discovery Boston, MA 2008
NeoDiagnostix Biotechnology Gaithersburg, MD 0000
To view Celgene’s complete subsidiaries history, request access »

Celgene Exits (75)

Company Name Exit Date Exit Type Exit Size Status Buyers
Oncorus 20-Dec-2019 00000 00000 00 000.00 Completed
  • 17 buyers
Cyteir Therapeutics 15-Oct-2019 00000 00000 00 000.00 Completed
  • 6 buyers
RAPT Therapeutics 18-Jun-2019 00000 00000 00 0000 Completed
  • 6 buyers
BeCareLink 10-May-2019 00000 0000 Completed
  • 2 buyers
Vividion Therapeutics 30-Apr-2019 Later Stage VC 0000 Completed
  • 12 buyers
You’re viewing 5 of 75 exits. Get the full list »

Celgene FAQs

  • When was Celgene founded?

    Celgene was founded in 1986.

  • Who is the founder of Celgene?

    David Stirling Ph.D and Robert Hariri Ph.D are the founders of Celgene.

  • Where is Celgene headquartered?

    Celgene is headquartered in Summit, NJ.

  • What is the size of Celgene?

    Celgene has 8,852 total employees.

  • What industry is Celgene in?

    Celgene’s primary industry is Drug Discovery.

  • Is Celgene a private or public company?

    Celgene is a Private company.

  • What is the current valuation of Celgene?

    The current valuation of Celgene is 000.00.

  • What is Celgene’s current revenue?

    The current revenue for Celgene is 00000.

  • How much funding has Celgene raised over time?

    Celgene has raised $5.01B.

  • Who are Celgene’s investors?

    Asseily Ventures, BB Biotech, CHL Medical Partners, Edelson Technology Partners, and Ridgeback Capital have invested in Celgene.

  • Who are Celgene’s competitors?

    Seagen, Incyte, Gilead Sciences, Merck & Co., and Emmaus Life Sciences are some of the 27 competitors of Celgene.

  • When was Celgene acquired?

    Celgene was acquired on 20-Nov-2019.

  • Who acquired Celgene?

    Celgene was acquired by Bristol-Myers Squibb.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »